KEVIN CHESSMORE: Open Payments
NPI 1730225913 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 36 payments from 12 companies in 2025. Trend: 2023 $399 · 2024 $742 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $157 |
| Lilly USA, LLC | 8 | $110 |
| ABBVIE INC. | 6 | $108 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $105 |
| Viatris Specialty LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| CeQur Corporation | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
Products named: FARXIGA, MOUNJARO, VRAYLAR, Kerendia, BREZTRI, YUPELRI, GEMTESA, CeQur Simplicity.
Industry payments across OK — which companies pay providers there.
